Definitions, prevalence, and mental health concerns
===================================================

While a person\'s \"sex\" refers to the physical attributes that characterize biologic maleness or femaleness (e.g., the genitalia), \"gender identity\" refers to a person\'s inner sense of self as male or female and is not always binary. At birth, most children are assigned a \"sex of rearing\" based on genital anatomy. With that assignment comes societal expectations of gender roles, behaviors, and expressions, which are sometimes referred to as a child\'s \"assigned (or natal) gender\"[@B1]. Despite the practice of \"assigning\" a gender in the newborn period, it is important to note that gender identity can only be assumed, and not, in fact, known until an individual achieves a particular level of psychological development and self-awareness. An individual for whom gender identity and physical sex characteristics are in alignment is sometimes referred to as \"cisgender.\"

\"Gender nonconforming\" is a term sometimes used when gender identity is not consistent with the gender assumed based on birth sex assignment[@B1]. The term \"Transgender\" has been used to describe a person who transiently or persistently identifies with a gender different from their \"natal gender\"[@B2]. The World Professional Association for Transgender Health (WPATH) Standards of Care (SOC) describes \"transgender\" (adjective) as \"a diverse group of individuals who cross or transcend culturally defined categories of gender\" and transsexual\" (adjective) as \"individuals who seek to change or have changed their primary and/or secondary sex characteristics through feminizing or masculinizing medical interventions (hormones and/or surgery), typically accompanied by a permanent change in gender role.\"[@B3]. \"Transsexual\" has also been used to describe a person who identifies as a member of the gender opposite to that assigned at birth[@B4][@B5], but who has not necessarily sought medical and/or surgical interventions.

\"Transgender,\" defined more narrowly, refers to an individual whose gender identity is the \"opposite\" of their \"assigned\" or \"natal gender.\" A person with a female gender identity and male assigned sex would be referred to as a \"transgender girl/woman,\" \"transfemale,\" or MTF (male to female); a person with a male gender identity and female assigned sex would be referred to as a \"transgender boy/man,\" \"transmale,\" or FTM[@B6].

\"Gender behavior\" is not equivalent to gender identity, and the majority of youth with gender non-conforming behavior will not turn out to have a transgender identity[@B4][@B5][@B7][@B8]. In the *Diagnostic and Statistical Manual of Mental Disorders* (DSM) 5, \"Gender dysphoria\" refers to clinically significant distress (of at least 6 month\'s duration) related to the incongruence between one\'s \"affirmed\" or \"experienced gender\" and one\'s \"assigned (or natal) gender.\" This term replaces \"Gender Identity Disorder\" (GID) found in the earlier DSM IV. Replacing \"disorder\" with \"dysphoria\" underscores the concept that a transgender identity is no longer considered pathological, and instead, focuses on dysphoria as the clinical concern[@B2].

\"Sexual identity\" (or \"sexual orientation\") is often confused with \"gender identity.\" While the former refers to whom one is sexually attracted, the latter refers to whom one \"is\" as male, female, or somewhere on the gender continuum. Any individual, whether transgender or cisgender, may have any sexual orientation.

The prevalence of transgender youth is not known. However, multidisciplinary clinics for transgender youth and adolescents in Europe and North America and some parts of Asia (personal communication) have seen a steadily increasing demand for services in recent years[@B9][@B10][@B11][@B12]. Studies in adults suggest that the prevalence of being transgender may be as high as 1 in 200 individuals[@B13].

Regarding mental health considerations, transgender youth/young adults had a 2- to 3-fold increased risk of anxiety, depression, suicidal ideation, suicide attempts, and self-harm without lethal intent in comparison to controls[@B14]. The impact of the degree of parental support on mental health outcomes was reported in transgender youth and young adults age 16 to 24 years (n=84) from Ontario, Canada: Satisfaction with life and self-esteem were significantly greater in transgender youth whose parents were \"very supportive\" vs. those whose parents were \"somewhat to not at all supportive\"[@B15]. In addition, depression and suicide attempts were significantly decreased in transgender youth whose parents were supportive in comparison to those whose parents were not supportive[@B15].

Biological determinants of gender identity
==========================================

Numerous studies from a variety of biomedical disciplines---endocrine, genetic, and neuroanatomical---have begun to shed light on the biological determinants of gender identity[@B16]. Results of these studies support the concept that gender identity is not simply a psychosocial construct, but likely reflects a complex interplay of biologic, environmental, and cultural factors.

While the majority of transgender patients do not have a disorder/difference of sex development (DSD), studies of gender identity outcome within the endocrine discipline have been principally carried out in patients with a variety of DSDs, primarily exploring the role of prenatal and postnatal androgens in gender identity development. For example, in studies of 46, XX patients with \"classical\" congenital adrenal hyperplasia (CAH) caused by mutations in the *CYP21A2* gene resulting in 21-hydroxylase deficiency and varying degrees of genital masculinization, there was a greater than expected number of patients with gender dysphoria, \"atypical gender identity\", or who were transgender[@B17][@B18][@B19]. In a meta-analysis of 250 patients with 46, XX 21-hydroxylase deficiency leading to virilizing CAH and raised female, nearly 95% of patients reported a female gender identity without gender dysphoria, while 5.2% reported either a male gender identity or gender dysphoria[@B18]. Of note, there was no apparent correlation with the degree of genital masculinization and gender identity outcome[@B18]. This and other studies demonstrate that the majority of 46, XX patients with virilizing CAH from 21-hydroylase deficiency appear to have a female gender identity. However, the finding that 5.2%--11.6% of such patients have gender dysphoria, an \"atypical gender identity\" or are transgender would appear to be much more common than expected based on the reported prevalence of FTM transsexualism, implying that there is some role for prenatal/postnatal androgens in gender identity outcome[@B17][@B18][@B19]. It is noteworthy that in 46, XX individuals with virilizing CAH from 21-hydroylase deficiency, prenatal androgens are more likely to affect gender behavior and sexual orientation than gender identity[@B20][@B21].

The potential effects of prenatal and postnatal androgen exposure on gender identity outcome and \"gender role change\" have also been explored in other hormonal and nonhormonal DSDs[@B22][@B23][@B24][@B25][@B26]. These studies indicate that gender identity is not solely dependent on prenatal and postnatal androgen exposure; however, the occurrence of gender identity change (in comparison to the \"natal gender\") at a rate significantly higher than would be expected in the general population supports some role of prenatal and possibly postnatal androgens in gender identity development. While the above-noted studies support some role of androgens in male gender identity, a case report in a 46, XY individual with Complete Androgen Insensitivity Syndrome challenges the concept that androgen receptor signaling is required for male gender identity development[@B27]. Potential limitations of all these survey/questionnaire-based studies to assess gender identity include a person\'s degree of self-awareness and one\'s willingness to disclose this information in the study context[@B16].

With respect to genetics and gender identity, heritability of transsexualism has been suggested primarily from studies describing concordance of transsexualism in monozygotic twin pairs[@B28][@B29][@B30][@B31]. A study supporting a role for genetic factors in gender identity outcome demonstrated a 39.1% concordance for GID (based on DSM-IV criteria) in 23 monozygotic female and male twin pairs, with no concordance in 21 same-sex dizygotic female and male twin pairs or in 7 opposite-sex twin pairs[@B31]. However, with respect to specific candidate genes, association studies of polymorphisms with transsexualism have been inconsistent and lacking strong statistical significance[@B32][@B33][@B34][@B35].

Regarding neuroanatomical considerations and gender identity, it has been known for some time that some brain structures are sexually dimorphic, while one component of the hypothalamus has been reported to be sexual orientation-dimorphic[@B16]. Numerous studies in transgender adults, carried out prior to any cross-sex hormone treatment, have provided evidence indicating that some sexually dimorphic structures appear to align more closely with a person\'s gender identity than with their physical sex characteristics[@B16]. A trend towards similar findings has also been reported in gray matter of gender dysphoric youth[@B36].

Natural history of transgender youth
====================================

The majority of gender dysphoric prepubertal youth will no longer meet the mental health criteria for gender dysphoria once puberty has begun, likely reflecting the heterogenous nature of this group[@B2][@B7][@B8][@B37]. Investigators have attempted to identify factors that predict gender dysphoria \"persisters\" versus \"desisters\"[@B38]. Persisters reported relatively greater degrees of gender dysphoria and were more likely to have experienced social transition (to their affirmed gender) during childhood[@B38]. In addition, persisters believed they \"were\" the other sex, while desisters \"wished they were\" the other sex[@B38]. The limitations in prediction of persistence, coupled with the observation that most gender dysphoric children will not become transgender adolescents or adults, have led some investigators and/or practitioners to promote efforts to encourage gender dysphoric children to accept their natal gender[@B39]. In contrast, a model of care that \"affirms\" a child\'s gender expression is thought to have a more optimal mental health outcome[@B1][@B40]. Long-term outcomes studies are needed to resolve these differences in approach to the care of gender dysphoric pre-pubertal youth.

Multidisciplinary care of transgender youth
===========================================

Persistence of gender dysphoria following initiation of puberty implies a very high likelihood that such individuals will be transgender as adults; in fact, the emergence or worsening of gender dysphoria with onset of puberty is thought to have significant diagnostic value in the determination of being transgender[@B41]. Given the complexity of these issues, it is essential that gender dysphoric youth undergo a thorough psycho-diagnostic evaluation by a qualified mental health provider. An important role of the mental health/gender specialist is not only to determine the presence or absence of gender dysphoria, but to also evaluate for the presence of other mental health concerns. For example, while there is an increased association of gender dysphoria and autism spectrum disorder[@B42][@B43], the majority of gender dysphoric children and adolescents do not have an underlying severe psychiatric illness[@B41].

Based on pioneering work form the Netherlands, the Endocrine Society (ES) guidelines and WPATH SOC endorse the use of pubertal blockers using gonadotropin releasing hormone (GnRH) agonists at Tanner stage II/III in individuals experiencing a significant increase in gender dysphoria with onset of puberty[@B3][@B4][@B44][@B45][@B46][@B47]. This treatment is fully reversible and allows additional time for gender exploration without the pressure of ongoing pubertal development. The physical changes of puberty, once completed, cannot be reversed (by means other than surgical or, for voice, other than by voice training)---e.g., low voice, Adam\'s apple, and facial features in phenotypic males and breast development in phenotypic females. Preventing pubertal development that does not match a person\'s gender identity can theoretically lead to decreased distress, and can ultimately enable the individual to more easily \"blend\" in society as an adult. Subsequently, if the individual continues to identify as transgender, cross-sex hormones can be added while continuing GnRH agonist suppression of endogenous puberty, enabling the individual to experience only the physical changes of puberty that match the person\'s experienced/affirmed gender identity[@B3][@B4]. While age-specific guidelines for subsequent interventions are not delineated in the WPATH SOC, the ES guidelines suggest that cross-sex hormones can be initiated at about the age of 16 years (the legal age for medical decision-making in some countries), while surgical procedures (with the exception of mastectomy) should be deferred until the individual is at least 18 years of age[@B4]. Delaying cross-sex hormone treatment until age 16 could not only be detrimental to bone health, but, by keeping someone in a prepubertal state until this age, would isolate the individual further from age-matched peers, with potentially negative consequences for emotional well-being. Gender centers at our institution and elsewhere are therefore studying the impact of cross-sex hormone treatment initiation at 14 years of age (which approximates the upper end of the age range for normal pubertal onset in natal males and one year beyond the upper end of the age range in natal females). In this group, sex steroids are increased gradually over the course of 2--3 years[@B16].

There are currently only limited outcomes data to support the ES and WPATH recommendations for care of transgender youth. A report from the Netherlands assessed mental health outcomes in 55 transgender adolescents/young adults (22 MTF, 33 FTM) at 3-time points: Before the start of GnRH agonist treatment, at initiation of cross-sex hormones (average 16.7 years at start of treatment), and at least 1 year after \"gender reassignment surgery\" (average age 20.7 years)[@B48]. Despite a decrease in depression and an improvement in general mental health functioning, gender dysphoria persisted during the period of pubertal suppression (as noted in earlier reports); however, following cross-sex hormone treatment and \"gender reassignment surgery,\" gender dysphoria was resolved and psychological functioning steadily improved[@B48]. \"Well-being\" was found to be similar to or better than that in age-matched young adults from the general population, and none of the study participants regretted treatment[@B48]. This study represents the first long-term follow-up of patients managed according to currently existing clinical practice guidelines for transgender youth, and underscores the benefit of the multidisciplinary approach to care.

The primary risks of pubertal suppression in gender dysphoric youth treated with GnRH agonists include adverse effects on bone mineralization, compromised fertility, and unknown effects on brain development.

A 6-year longitudinal, observational study assessed bone mineral density (BMD) in 34 transgender adolescents (15 MTF, 19 FTM) who had received GnRH agonist beginning at an average age of 14.9--15 years (individuals were mid-late pubertal at study onset by testicular volume or breast stage), had initiation of cross sex hormones at 16.4--16.6 years, followed by gonadectomy with discontinuation of GnRH agonist at a minimum age of 18 years[@B49]. Over the 6-year observation period, areal BMD Z-scores decreased significantly in MTF individuals with a trend for a decrease in FTM individuals, suggesting either a delay in attainment of peak bone mass, or an attenuation of peak bone mass, itself[@B49]. As acknowledged by the authors, potential study limitations included a relatively small \"n,\" the fact that individuals were already late pubertal at the time of GnRH agonist initiation, the possibility that relatively low doses of cross sex hormones were used during the initial period of that phase of treatment, and that information was not available regarding dietary calcium intake, Vitamin D levels, and weight bearing exercise, all of which can influence BMD[@B49]. It would seem important, particularly during GnRH agonist treatment, to ensure adequate intake of calcium and Vitamin D, to encourage weight-bearing exercise, and to routinely monitor levels of 25-OH Vitamin D[@B16].

Any use of pubertal blockers and cross-sex hormones in transgender youth should include an informed consent process and a discussion about implications for fertility. Transgender adolescents may wish to preserve fertility, which may be otherwise compromised if puberty is suppressed at an early stage and the patient completes phenotypic transition with the use of cross-sex hormones[@B16]. While full *in vitro* maturation of germ cells has not yet been achieved in humans, promising studies have been carried out in mice[@B50][@B51].

Regarding potential adverse effects of GnRH agonists (and cross sex hormones) on brain, a recent study investigated whether GnRH agonist treatment of gender dysphoric adolescents would impair executive functioning (reasoning, problem solving, etc.), thought to reflect pre-frontal brain activation, and to have significant development during puberty[@B52]. No significant detrimental effects of GnRH agonist treatment on executive functioning were observed[@B52].

Some transgender adolescents first come to medical attention when they are late pubertal (Tanner stage IV/V). FTM individuals can be treated with testosterone alone while MTF individuals are optimally treated with estrogen with concurrent use of an agent that blocks testosterone secretion and/or action[@B3][@B4]. In this older cohort, cross sex hormone regimens may be increased to full replacement doses over a shorter interval than used for the younger cohort that had been initially treated with pubertal blockers at Tanner II/III[@B16]. While GnRH agonists are the preferred option for pubertal suppression in both the early and late pubertal individuals, this treatment is costly and often inaccessible[@B16]. Options for pubertal suppression and cross sex hormone treatment are listed in [Table 1](#T1){ref-type="table"}[@B16]. With respect to estrogen treatment, 17 β-estradiol (transdermal, oral, or parenteral) is preferred to conjugated (e.g., premarin) or synthetic estrogens (e.g., ethinyl estradiol) given that conjugated and synthetic estrogen levels cannot be monitored in the serum and that ethinyl estradiol (in comparison to 17 β-estradiol) is associated with an increased risk for venous thromboembolic disease and death from cardiovascular causes[@B53][@B54]. [Table 2](#T2){ref-type="table"}[@B16] summarizes surveillance recommendations for desired as well as adverse effects during treatment with pubertal blockers alone and in combination with cross-sex hormones, adapted from the current ES guidelines[@B4].

Some Tanner stage IV/V-transgender adolescents present for medical services before 16 years of age. As with the group treated with GnRH agonists at early puberty, we and others are studying the consequences of cross-sex hormone treatment at 14 years of age[@B16]. Some gender dysphoric youth first come to medical attention when they are Tanner stage IV/V, but \<14 years of age. These individuals would be candidates for pubertal blockers (e.g., to stop menses in an FTM adolescent), but without supportive outcomes data, not currently candidates for cross-sex hormone use under most circumstances[@B16].

Challenges to optimal care and priorities for research
======================================================

Areas of uncertainty and barriers to state-of-the art practice limit the ability to provide optimal health care to gender dysphoric/transgender youth. Currently, there are only limited safety and efficacy studies, with virtually no published data on the use of pubertal blockers in gender dysphoric individuals \<12 years of age or cross-sex hormones in transgender youth \<16 years of age. In addition, randomized controlled trials for hormonal interventions in gender dysphoric youth have not been considered feasible or ethical[@B55]. Current clinical practice guidelines are based on best available evidence, with significant reliance on expert opinion. While an increasing number of clinical programs have emerged around the world in recent years, there are many geographic regions in which such services do not exist, limiting access to care and often requiring patients and families to travel long distances. Furthermore, lack of training of providers and prejudice and misunderstanding on the part of family, community, and medical and mental health professionals may limit access to optimal care[@B56].

Conclusions
===========

While significant advances in our understanding of gender nonconforming/transgender youth have been achieved, many gaps in knowledge remain. Compelling studies have demonstrated that gender identity is not simply a psychosocial construct, but likely reflects a complex interplay of biologic, environmental, and cultural factors[@B16]. The replacement of \"disorder\" with \"dysphoria\" in DSM-5 removes the connotation that a transgender identity, itself, is pathologic, and instead, focuses on dysphoria as the clinical concern[@B2]. A landmark study from the Netherlands indicates that mental health co-morbidities in gender-dysphoric youth significantly diminish or resolve when such individuals are subject to a gender-affirming model of care, optimally delivered in a multi-disciplinary clinical setting[@B48]. Further prospective studies focused on long-term safety and efficacy are necessary to optimize medical and mental health care for transgender youth.
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###### Hormonal interventions for transgender adolescents (All currently off-label for gender nonconforming/transgender youth)

![](apem-21-185-i001)

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  A. Inhibitors of gonadal sex steroid secretion or action
   1. GnRH analogues: Inhibition of the hypothalamic-pituitary-gonadal (HPG) axis (FTM and MTF)
    a. Leuprolide acetate IM (1- or 3-month preparations) or SC (1-, 3-, 4-, or 6-month preparations) at dose sufficient to suppress pituitary gonadotropins and gonadal sex steroids
    b. Histrelin acetate SC implant (once-yearly dosing, though may have longer effectiveness)
    c. Other options: goserelin acetate SC implant (4- or 12-week preparations); nafarelin acetate Intranasal (multiple daily doses) also available, but no reported use in this population
   2. Alternative approaches
    a. Medroxyprogesterone acetate orally (up to 40 mg/day) or IM (150 mg q 3 months): Inhibition of HPG axis and direct inhibition of gonadal steroidogenesis (FTM an MTF)
    b. Spironolactone (25 to 50 mg/day with gradual increase to 100--300 mg/day orally, divided into BID dosing): Inhibition of testosterone synthesis and action (MTF)
    c. Cyproterone acetate (gradual increase up to 100 mg/day orally; not available in U.S.): Inhibition of testosterone synthesis and action (MTF)
    d. Finasteride (2.5--5 mg/day orally)
     Inhibition of type II 5 α-reductase, blocking conversion of testosterone to 5 α-dihydrotestosterone (MTF)
  B. Cross-sex hormones
   1. MTF: Estrogen: 17 β-estradiol
    a. Transdermal: twice weekly patches (6.25 mcg \[achieved by cutting a 25 mcg patch\] with gradual increase to full adult dose)
    b. Oral/sublingual: daily (0.25 mg with gradual increase to full adult dose of 2--6 mg/day)
    c. Parenteral IM (synthetic esters of 17 β-estradiol): estradiol valerate (5--20 mg up to 30--40 mg q 2 weeks) or estradiol cypionate (2--10 mg q 1 week)
   2. FTM: Testosterone
    a. Parenteral IM or SC (synthetic esters of testosterone): testosterone cypionate or enanthate (12.5 mg q week or 25 mg q 2 weeks, with gradual increase to 50--100 mg q week or 100--200 mg q 2 weeks)
    b. Transdermal (consider once full adult testosterone dose has been achieved parenterally): patch (2.5--7.5 mg/day) or 1% gel (2.5--10 grams/day of gel = 25--100 mg/day of testosterone)
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

GnRH, gonadotropin releasing hormone; IM, intramuscular; SC, subcutaneous; FTM: female-to-male; MTF, male-to-female; q, every.

Adapted from Rosenthal SM. J Clin Endocrinol Metab 2014;99:4379-89, with permission of .the Endocrine Society[@B16].

###### Monitoring during pubertal suppression and during cross-sex hormone treatment^\*^
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  -------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------
  A. Pubertal suppression                                                                                                                                        
   Measure                                                                                                                                                        Frequency
    1. Physical exam: height, weight, Tanner staging                                                                                                             T 0 & q 3 mo
    2. Hormonal studies: ultrasensitive LH, FSH, estradiol/testosterone                                                                                          T 0 & q 3 mo
    3. Metabolic: Ca, phos, alk phos, 25-OH vitamin D (see also ref. 3)                                                                                          T 0 & q 1 yr
    4. Bone density: DEXA                                                                                                                                        T 0 & q 1 yr
    5. Bone age                                                                                                                                                  T 0 & q 1 yr
  B. Cross-sex hormone treatment in previously suppressed patients or in late pubertal patients not previously suppressed                                        
   Measure                                                                                                                                                        Frequency
    1. Physical exam: height, weight, Tanner staging, BP (for FTM, in particular); monitor for adverse reactions                                                 T 0 & q 3 mo^\*\*^
    2. Hormonal studies: ultrasensitive LH, FSH, estradiol/testosterone                                                                                          T 0 & q 3 mo^\*\*^
     If MTF: Also monitor prolactin                                                                                                                              T 0 & q 1 yr
    3. Metabolic: Ca, phos, alk phos, 25-OH vitamin D, complete blood count, renal & liver function, fasting lipids, glucose, insulin, glycosylated hemoglobin   T 0 & q 3 mo^\*\*^
     If MTF on spironolactone: serum electrolytes (potassium)                                                                                                    T 0 & q 3 mo^\*\*^
  4\. Bone density: DEXA (if puberty previously suppressed)                                                                                                      T 0 & q 1 yr^\*\*\*^
  5\. Bone age (if puberty previously suppressed)                                                                                                                T 0 & q 1 yr^\*\*\*^
  -------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------

LH, luteinizing hormone; FSH, follicle stimulating hormone; DEXA, dual-energy X-ray Absorptiometry; BP, blood pressure; FTM: female-to-male; MTF, male-to-female; q, every.

^\*^Modified from reference 4; ^\*\*^q 3-12 months after 1st year; ^\*\*\*^Until puberty is completed.

Adapted from Rosenthal SM. J Clin Endocrinol Metab 2014;99:4379-89, with permission of .the Endocrine Society[@B16].
